Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

CanSino Biologics, Inc. Class H (CJH) Stock Price & Analysis

1 Followers

CJH Stock Chart & Stats

€2.90€0.00(0.00%)
At close: 5:30 PM GMT+1
€3€3.5€4€4.5Sep 4Sep 30Oct 8Oct 29
Day’s Range
EUR 2.86 - EUR 2.90
52-Week Range
EUR 2.28 - EUR 5.25
Previous Close
EUR 2.90
Volume
N/A
Average Volume (3M)
79
Market Cap
EUR 1.49B
Enterprise Value
EUR 8.04B
Total Cash (Recent Filing)
EUR 1.77B
Total Debt (Recent Filing)
EUR 929.08M
Price to Earnings (P/E)
575.1
Beta
1.16
Next Earnings
Mar 30, 2027 (Est.)
EPS Estimate
0.04
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Revenue Rebound

The strong TTM revenue rebound and renewed growth in 2024–2025 indicate recovering commercial demand and improved business traction. If this momentum persists, higher sales can support greater manufacturing utilization, broaden market reach, and provide a stronger base for future profitability.

Moderate Leverage

Moderate and improving leverage gives CanSino greater financial flexibility while it operates in a business with uneven profitability and substantial development needs. A sizable equity base can help the company fund operations and pursue vaccine opportunities without relying excessively on debt.

Positive Operating Cash Flow

The return to positive operating cash flow suggests that the company’s core activities are beginning to generate cash internally after weaker prior periods. Continued improvement would strengthen funding capacity for vaccine development, regulatory work, and commercial operations without depending entirely on external capital.

Bears Say

Negative Free Cash Flow

Negative free cash flow means reported operating activity is not yet covering investment needs, limiting the cash available for strategic initiatives and balance-sheet strengthening. The persistence of negative free cash flow across prior years raises concern that revenue recovery may require continuing financial support.

Fragile Operating Profitability

Slightly negative EBIT and a history of highly volatile margins make it difficult to establish that recent earnings improvement is durable. Until operating profitability becomes consistently positive, fluctuations in sales, product mix, or investment spending could quickly reverse modest net income.

Weak Returns On Equity

Very low current ROE indicates that CanSino is generating limited profit from its equity base despite the recent return to modest net income. Persistently weak capital returns could constrain retained-earnings growth and indicate that the company has not yet converted its asset base into efficient, durable value creation.

CanSino Biologics, Inc. Class H News

CJH FAQ

What was CanSino Biologics, Inc. Class H’s price range in the past 12 months?
CanSino Biologics, Inc. Class H lowest stock price was €2.28 and its highest was €5.25 in the past 12 months.
What is CanSino Biologics, Inc. Class H’s market cap?
CanSino Biologics, Inc. Class H’s market cap is €1.49B.
When is CanSino Biologics, Inc. Class H’s upcoming earnings report date?
CanSino Biologics, Inc. Class H’s next earnings report is estimated for Mar 30, 2027 (not yet confirmed), which is in 146 days.
How were CanSino Biologics, Inc. Class H’s earnings last quarter?
CanSino Biologics, Inc. Class H released its earnings results on Oct 27, 2026. The company reported €0.009 earnings per share for the quarter, missing the consensus estimate of €0.034 by -€0.024.
Is CanSino Biologics, Inc. Class H overvalued?
According to Wall Street analysts CanSino Biologics, Inc. Class H’s price is currently Undervalued.
Does CanSino Biologics, Inc. Class H pay dividends?
CanSino Biologics, Inc. Class H does not currently pay dividends.
What is CanSino Biologics, Inc. Class H’s EPS estimate?
CanSino Biologics, Inc. Class H’s EPS estimate is 0.04.
How many shares outstanding does CanSino Biologics, Inc. Class H have?
CanSino Biologics, Inc. Class H has 132,670,900 shares outstanding.
What happened to CanSino Biologics, Inc. Class H’s price movement after its last earnings report?
CanSino Biologics, Inc. Class H reported an EPS of €0.009 in its last earnings report, missing expectations of €0.034. Following the earnings report the stock price went down -5.521%.
Which hedge fund is a major shareholder of CanSino Biologics, Inc. Class H?
Currently, no hedge funds are holding shares in DE:CJH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology